Quince Therapeutics, Inc. balance sheet IRLA

Annual Quarterly

As of Jun 30, 2026, Quince Therapeutics, Inc. had total assets of $124.0 million and total liabilities of $15.5 million. Total assets were up 5.8% from a year earlier. Stockholders' equity was negative, at -$35.3 million, because liabilities exceed assets. It held $116.0 million in cash and investments against $445,000 of total debt, net cash of $115.5 million. The current ratio, current assets divided by current liabilities, was 14.52.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

FY 2026
Jun 30, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2020
Dec 31, 2020
FY 2019
Dec 31, 2019
Assets
Cash
116
+589.3%
6
—
—
—
—
—
51
Short-term investments
0
—
35
-36.3%
54
+19.1%
46
+23.0%
37
-44.6%
67
+37.7%
49
Long-term investments
—
—
—
0
-100.0%
4
-82.0%
20
-60.5%
50
+201.0%
17
Cash and investments
116
+589.3%
6
-83.2%
35
-36.3%
54
+10.4%
49
-13.7%
57
-51.5%
117
+0.7%
117
Total current assets
123
+230.5%
23
-48.0%
44
-43.1%
77
-17.4%
94
-16.1%
112
-19.0%
138
+30.0%
106
Property and equipment, net
1
-11.7%
1
+88.9%
0
+34.6%
0
-40.5%
0
+49.4%
0
-38.4%
0
-39.8%
1
Goodwill
—
—
0
-100.0%
18
0
—
—
—
Total assets
124
+5.8%
94
-18.3%
114
-31.8%
168
+61.6%
104
-22.0%
133
-29.7%
189
+52.3%
124
Liabilities and equity
Accounts payable
5
+163.6%
2
-23.4%
3
+42.8%
2
+256.7%
1
-88.4%
5
+38.1%
4
+15.6%
3
Total current liabilities
8
+13.8%
43
+493.9%
7
-24.0%
10
+211.9%
3
-78.4%
14
-16.3%
17
+91.1%
9
Total liabilities
16
-85.3%
129
+53.2%
84
+1.8%
83
+2396.7%
3
-77.3%
15
-14.9%
17
+93.5%
9
Stockholders' equity
-35
-401.0%
-36
-218.5%
30
-64.6%
85
-15.4%
101
-15.2%
119
-31.2%
172
+49.2%
115
Debt
Debt due within a year
0
18
—
—
—
—
—
—
Long-term debt
—
0
-100.0%
14
+6.6%
13
—
—
—
—
Lease liabilities
0
-10.8%
0
-9.2%
0
+7.7%
0
+2.1%
0
-67.5%
1
+160.3%
0
0
Total debt
0
-97.5%
18
+24.7%
15
+6.7%
14
+3564.2%
0
-67.5%
1
+160.3%
0
0
Net cash
116
+17552.6%
-13
-164.1%
20
-51.1%
40
-17.0%
49
-12.6%
56
-52.3%
117
+0.3%
117
Ratios
Current ratio
14.52x
0.53x
6.05x
8.09x
30.55x
7.85x
8.11x
11.93x
Debt to equity
—
—
0.49x
0.16x
0.00x
0.01x
0.00x
0.00x
Return on equity
—
—
-188.51%
-36.89%
-51.36%
-75.85%
-44.61%
-32.02%
Return on assets
-74.58%
-89.80%
-49.64%
-18.69%
-49.72%
-67.51%
-40.56%
-29.73%
Book value per share
-34.73
-128.18
0.69
1.98
2.78
3.94
5.83
4.30
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
IRLA (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
New Haven, CT
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1662774
Former names
Quince Therapeutics, Inc. (until Oct 9, 2026); Cortexyme, Inc. (until Aug 1, 2022)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.